Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Sagimet Biosciences Inc. Series A Common Stock(SGMT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SGMT
09/28/2026: SGMT (4-star) is a SELL. SELL for 3 days. Simulated Profits (47.17%). Updated daily EoD!
Sagimet Biosciences is a clinical-stage biotechnology company focused on developing denifanstat, a proprietary FASN inhibitor designed to treat MASH. The company is currently in the critical Phase 3 development phase, representing a high-risk, high-reward opportunity for investors. Its primary strength lies in its specialized, single-indication focus, though this concentration creates significant binary risk if clinical results fail to meet regulatory standards. Valuation remains speculative as the company generates no product revenue and relies on external financing. Retail investors should closely monitor clinical trial milestones and the company's cash runway, keeping in mind that this stock is suited only for those comfortable with high volatility and long-term scientific uncertainty.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk growth play that depends entirely on future clinical and regulatory success. |
| Momentum investor | Mixed fit | Momentum may occur around clinical data catalysts, but the stock lacks a stable, trending business foundation. |
| Value investor | Weak fit | Traditional value metrics like P/E are not applicable as the company is not yet profitable. |
| Dividend investor | Weak fit | The company is in an early growth phase and pays no dividends. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology stocks are highly volatile and carry extreme downside risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results often cause extreme price swings in either direction. |
| Valuation risk | Medium / high | Valuation is based on speculative future drug approval rather than current earnings. |
| Competition risk (MASH drug developers) | High | Competitors with approved drugs may capture market share before Sagimet reaches the market. |
| Business quality | Medium | The company has a focused science-driven approach, but lacks the diversified revenue streams of established firms. |
| Dividend income | Low / none | The company reinvests all cash into R&D and provides no income to investors. |
| Execution risk | High | Success depends on the complex execution of global Phase 3 trials and regulatory approval processes. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 196.7% | Avg. Invested days 43 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 617.86M USD | Price to earnings Ratio - | 1Y Target Price 27.55 |
Price to earnings Ratio - | 1Y Target Price 27.55 | ||
Volume (30-day avg) 1.1M shares | Beta 3.49 | 52 Weeks Range 4.50 - 11.45 | Updated Date 09/28/2026 |
52 Weeks Range 4.50 - 11.45 | Updated Date 09/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.26 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Clinical and preclinical efforts centered on FASN inhibitor denifanstat. | The company currently spends money to develop a drug and does not yet generate product sales revenue. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 408.88M | Price to Sales(TTM) 52.5 |
Enterprise Value 408.88M | Price to Sales(TTM) 52.5 | ||
Enterprise Value to Revenue 0.28 | Enterprise Value to EBITDA -1.93 | Shares Outstanding 61.59M | Shares Floating 55.78M |
Shares Outstanding 61.59M | Shares Floating 55.78M | ||
Percent Insiders 3.35 | Percent Institutions 83.15 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Sagimet Biosciences Inc. Series A Common Stock
Exchange NASDAQ | Headquarters San Mateo, CA, United States | ||
IPO Launch date 2023-07-14 | CEO, President & Director Mr. David A. Happel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.sagimet.com |
Full time employees 16 | Website https://www.sagimet.com | ||
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.